Infecções graves em pacientes com artrite reumatoide em uso de anakinra, rituximab ou abatacept: revisão sistemática de estudos observacionais

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

(2015) Jasvinder A Singh et al.   LANCET

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis

(2014) J. R. Curtis et al.   ARTHRITIS CARE & RESEARCH

Observational Studies of Infections in Rheumatoid Arthritis: A Metaanalysis of Tumor Necrosis Factor Antagonists

(2010) S. BERNATSKY et al.   JOURNAL OF RHEUMATOLOGY

Rheumatoid arthritis

(2010) David L Scott et al.   LANCET

Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis

(2010) Steven S. Storage et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

(2009) M. C. Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

(2008) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES